Raditrol 0.25

Indications of Rocaltrol 0.25 Capsule

• Established postmenopausal osteoporosis.
• Renal osteodystrophy in patients with chronic renal failure, particularly those undergoing hemodialysis.
• Postsurgical hypoparathyroidism.
• Idiopathic hypoparathyroidism.
• Vitamin D-dependent rickets.
• Hypophosphatemic vitamin D-resistant rickets.

 

Pharmacology of Rocaltrol 0.25 Capsule

Calcitriol is one of vitamin D3's most significant active metabolites. It is typically derived from its precursor, 25-hydroxycholecalciferol, in the kidneys. Calcitriol increases calcium absorption in the intestine and controls bone mineralization. Calcitriol's main function is to regulate calcium homeostasis, which involves stimulation of osteoblastic activity in the skeleton.

 

Dosage & Administration of Rocaltrol 0.25 Capsule

Standard dosage: The optimal daily dose of Rocaltrol@ must be carefully determined for each patient on the basis of the serum calcium level. Rocaltrol@ therapy should always be started at the recommended dose and increased only with careful monitoring of serum calcium. Once the optimal dosage of Rocaltrol@ has been determined, serum calcium levels should be checked monthly (or as stated below for individual indications). Samples for serum calcium estimation should be taken without a tourniquet. As soon as serum calcium rises to I mg/IOO ml (0.25 mmol/l) above normal levels (9—11 mg/IOO ml or 2.25—2 75 mmol/l) or serum creatinine rises to >120 p mol/l, treatment with Rocaltrol@ should be stopped immediately until normocalcemia is achieved. Serum calcium and phosphate levels must be determined daily as long as hypercalcemia persists. When normal levels have been restored, treatment with Rocaltrol@ can be continued at a daily dose 0.25 pg lower than that previously used. The prerequisite for optimal efficacy of Rocaltrol@ is adequate but not excessive calcium intake at the start of treatment. Calcium supplements may be required, which should be used in accordance with the current scientific recommendations. Because of improved calcium absorption from the gastrointestinal tract, it may be possible to reduce calcium intake in some patients taking Rocaltrol@ Patients with a tendency to hypercalcemia may require only low calcium doses or no supplementation at all.

 

Interaction of Rocaltrol 0.25 Capsule

Concurrent use of thiazide diuretics raises the risk of hypercalcemia. Calcitriol dose must be set with caution in patients receiving digitalis therapy, since hypercalcemia may induce cardiac arrhythmias. Hypermagnesemia can be caused by magnesium-containing medications (e.g., antiacids).

 

Contraindications

Calcitriol is not recommended for people who have a history of hypersensitivity to any of its components. Calcitriol is also contraindicated in all hypercalcemia-related illnesses.

 

Side Effects of Rocaltrol 0.25 Capsule

Anorexia, headache, vomiting, and constipation are all possible symptoms. Dystrophy, fever, polyuria, dehydration, apathy, and urinary tract infection are some of the long-term consequences.

 

Pregnancy & Lactation

In humans, there is no evidence that vitamin D is teratogenic. Calcitriol should only be taken during pregnancy if the benefits exceed the risks to the fetus. Mothers may breastfeed while taking Calcitriol, but their and their infant's blood calcium levels should be monitored.

 

Precautions & Warnings

If blood calcium levels rise to 1 mg/100 ml over normal or serum creatinine levels rise to >120 mol/l during Calcitriol therapy, the dosage of Calcitriol should be significantly decreased or treatment halted.

 

Therapeutic Class

Vitamins and Minerals

 

Storage Conditions

keep in a dry place away from light and heat. Keep out of the reach of children.

 

Pharmaceutical Name of Rocaltrol 0.25 Capsule

Radiant Pharmaceutical Ltd

 

Generic of Rocaltrol 0.25 Capsule

Calcitriol